Lyme disease Epidemiology Forecast, Diagnosis, Treatment Options | DelveInsight

Lyme disease Epidemiology Forecast, Diagnosis, Treatment Options | DelveInsight

Lyme disease Epidemiology Forecast to 2030


DelveInsight launched a new report on ‘Lyme disease Epidemiology Forecast to 2030′.

DelveInsight’s ‘Lyme disease Epidemiology Forecast to 2030′ report proffers an exhaustive coverage of the disease, aetiology, pathophysiology, symptoms, origins of the diseases, and prevailing epidemiological and treatment trends.

The report provides exhaustive coverage of historical epidemiological analysis and forecast for 7MM

  • The US
  • EU5
  • Japan

Some of the key facts of the report

1. Total Lyme Disease incident population in the seven major markets was 492,398 in 2017.
2. The total diagnosed incident population of Lyme disease in 7 major markets was 396,761 in 2017.
3. Japan had 82 diagnosed incident cases of Lyme disease in 2017.


Lyme disease market: Disease understanding and Epidemiological analysis

Lyme disease is an infectious disease caused by the Bacterium Borrelia burgdorferi, thus also known as Lyme burgdorferi. It is transmitted by the bite of black-legged ticks. The Lyme disease symptoms include headache, fever, fatigue, chills, and in most severe cases, people may begin to experience facial palsy, arthritis, and heart palpitations.

Lyme disease incidence has doubled since 1991, from about 4 cases per 100,000 people to 8 per 100,000 people, says CDC.

As per DelveInsight, total Lyme disease incident population in the 7MM was recorded 492,398 cases, whereas total diagnosed Lyme disease incident population was 396,761 for the study period 2017-28.



Request for sample pages :


Scope of the Report

  • The Lyme disease (LD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Lyme disease (LD) Epidemiology Report and Model provide an overview of the risk factors and global trends of Lyme disease (LD) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Lyme disease (LD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Lyme disease (LD)
  • The report provides the segmentation of the Lyme disease (LD) epidemiology


KOL- Views

We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Lyme disease (LD)?
  • What are the key findings pertaining to the Lyme disease (LD) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Lyme disease (LD) across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Lyme disease (LD)?
  • What are the currently available treatments of Lyme disease (LD)?


Reasons to buy

  • The Lyme disease (LD) Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global Lyme disease (LD) market
  • Quantify patient populations in the global Lyme disease (LD) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Lyme disease (LD) therapeutics in each of the markets covered
  • Understand the magnitude of Lyme disease (LD) population by its epidemiology
  • The Lyme disease (LD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Request for sample pages :


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population


Table of Contents

1. Key Insights

2. Executive Summary of Lyme Disease

3. Lyme Disease: Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

10. DelveInsight Capabilities

11. Disclaimer

*The above table of contents is not exhaustive; The complete ToC will be provided in the final report.


Related Reports:

The Lyme disease market report provides current treatment practices, emerging drugs, Lyme disease market share of the individual therapies, current and forecasted Lyme disease market Size from 2017 to 2030 segmented by seven major markets.

The Lyme Disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Lyme Disease across the complete product development cycle, including all clinical and nonclinical stages.


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NEVADA 89107
Country: United States